For Health Care Professionals Outside the US

The Unique Mechanism of Action of REVOLADE
Sets It Apart

REVOLADE complements, rather than competes with, endogenous thrombopoietin (TPO)1,2

  • REVOLADE uniquely binds to the transmembrane domain of TPO receptors, while endogenous TPO binds to the extracellular domain1,2
    • By not competing with endogenous TPO, REVOLADE can work together with endogenous TPO to promote platelet production2
  • As a small molecule, REVOLADE enters the bone marrow more effectively than endogenous TPO2,3

In patients with immune thrombocytopenia (ITP) (≥1 year of age) who failed their first therapy

REVOLADE Effectively Stimulates Platelet Production
And Does Not Promote Neutralising Antibodies2,4,5
View the MOA for REVOLADE in ITP

In adult patients with severe aplastic anaemia (SAA)

REVOLADE Has a Proven
Trilineage Response1,7

EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor.

View the MOA for REVOLADE in SAA
REVOLADE Restores Immune Tolerance
To Platelet Antigens9-11

REVOLADE may improve the function of CD4+ regulatory T cells (Tregs)9,11

  • REVOLADE may improve Tregs activity and reduce effector T helper functions9,11
  • This immunomodulatory activity may restore immune tolerance in ITP9-11

REVOLADE may help restore the natural balance of FΓ receptors (FcγR) that link antibody-mediated immunity and phagocytic activity9

  • REVOLADE may downregulate activating FcγRI and upregulate inhibitory FcγRIIb9
  • This rebalancing activity may reduce the platelet-targeted phagocytic activity of monocytes in ITP9,10

References:

1. REVOLADE Summary of Product Characteristics. February 2019. 2. Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833-2843. 3. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641-648. 4. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23. 5. Cheng G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3(3):155-164. 6. McCrae K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med. 2011;78(6):358-373. 7. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825. 8. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63-70. 9. Liu X, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128(6):852-861. 10. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807-2812. 11. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-4645.